BofA Securities Downgrades Cyteir Therapeutics to Neutral From Buy, Adjusts Price Target to 2 From 4 - Marketscreener.com

CYTDelisted Stock  USD 2.76  0.01  0.36%   
Slightly above 54% of Cyteir Therapeutics' investor base is interested to short. The analysis of current outlook of investing in Cyteir Therapeutics suggests that many traders are impartial regarding Cyteir Therapeutics' prospects. Cyteir Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Cyteir Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
BofA Securities Downgrades Cyteir Therapeutics to Neutral From Buy, Adjusts Price Target to 2 From 4 Marketscreener.com

Read at news.google.com
Google News at Macroaxis
  

Cyteir Therapeutics Fundamental Analysis

We analyze Cyteir Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyteir Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyteir Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Insiders

Shares Owned By Insiders Comparative Analysis

Cyteir Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Cyteir Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cyteir Therapeutics stock to make a market-neutral strategy. Peer analysis of Cyteir Therapeutics could also be used in its relative valuation, which is a method of valuing Cyteir Therapeutics by comparing valuation metrics with similar companies.

Peers

Cyteir Therapeutics Related Equities

MNOVMediciNova   6.63   
0%
100.0%
CSBRChampions Oncology   5.97   
0%
90.0%
NUVBNuvation Bio   4.53   
0%
68.0%
RZLTRezolute   3.95   
0%
59.0%
HCWBHCW Biologics   2.38   
0%
35.0%
NKTXNkarta   2.02   
0%
30.0%
CCCCC4 Therapeutics   0.81   
0%
12.0%
LYELLyell Immunopharma   0.72   
0%
10.0%
MOLNMolecular Partners   0.57   
0%
8.0%
GBIOGeneration Bio   0.34   
0%
5.0%
FHTXFoghorn Therapeutics   0.23   
0%
3.0%
SANASana Biotechnology   0.29   
4.0%
0%
GLUEMonte Rosa   0.54   
8.0%
0%
ANEBAnebulo Pharmaceuticals   1.86   
28.0%
0%
PRLDPrelude Therapeutics   2.56   
38.0%
0%
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Cyteir Stock

If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios